Targets › IL17A
13 programs from 12 companies in 35 trials: 14 Phase 3, 9 Phase 4, 7 Phase 1, 5 Phase 2; Immunology, Infectious disease, Oncology; next expected readout Dec 2026.
Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. (UniProt, Q16552)
Open in Phaseline: the race on IL17A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| First Hospital of China Medical University | Xeligekimab Injection IL-17A inhibitor monoclonal antibody | IL17A | Phase 4 | Palmoplantar Pustulosis (PPP) | Dec 2027 |
| Novartis | Secukinumab Interleukin 17A inhibitor | IL17A | Phase 4 | Non-radiographic Axial Spondyloarthritis; Hidradenitis Suppurativa (HS); Autoimmunity, Inflammation; Polymyalgia Rheumatica … | Feb 2028 |
| Psoriasis Treatment Center of Central New Jersey | Taltz Interleukin-17A (IL-17A) inhibitor | IL17A | Phase 4 | Psoriasis | – |
| UCB Biopharma SRL | Bimekizumab Interleukin 17A inhibitor; Interleukin-17F inhibitor | IL17A, IL17F | Phase 3 | Hidradenitis Suppurativa; Moderate to Severe Plaque Psoriasis; Palmoplantar Pustulosis; Enthesitis-related Arthritis … | Dec 2026 |
| MoonLake Immunotherapeutics | M-1095 Interleukin 17A inhibitor; Interleukin-17F inhibitor | IL17A, IL17F | Phase 3 | Hidradenitis Suppurativa; Arthritis, Psoriatic | Jan 2027 |
| Suzhou Suncadia Biopharmaceuticals | Vunakizumab (SHR-1314) Interleukin 17A inhibitor | IL17A | Phase 3 | Psoriatic Arthritis; Active Non-radiographic Axial Spondyloarthritis; Lupus Erythematosus, Systemic | Jan 2027 |
| Biocad | Netakimab IL-17A inhibitor monoclonal antibody | IL17A | Phase 3 | Plaque Psoriasis | Feb 2028 |
| Eli Lilly | Ixekizumab (LY2439821) Interleukin 17A inhibitor | IL17A | Phase 3 | Juvenile Psoriatic Arthritis; Plaque Psoriasis; Psoriasis Vulgaris; Type1 Diabetes Mellitus | Jan 2029 |
| Celltrion | Secukinumab (P55) Interleukin 17A inhibitor | IL17A | Phase 3 | Plaque Psoriasis | – |
| Sinocelltech | SCT650C Anti-IL-17A antibody | IL17A | Phase 2 | Hidradenitis Suppurativa (HS) | Mar 2027 |
| Zura Bio | Tibulizumab (ZB-106) Tumor necrosis factor ligand superfamily member 13B inhibitor; Interleukin 17A inhibitor | TNFSF13B, IL17A | Phase 2 | Hidradenitis Suppurativa (HS); Systemic Sclerosis (SSc) | Apr 2027 |
| Taizhou Mabtech Pharmaceutical | CMAB015 Interleukin-17A (IL-17A) inhibitor monoclonal antibody | IL17A | Phase 1 | Psoriasis | – |
| Celltrion | CT-P52 IL-17A inhibitor biosimilar | IL17A | Phase 1 | Healthy Participants | – |
Hidradenitis Suppurativa (HS) (3) Psoriasis (3) Plaque Psoriasis (3) Moderate to Severe Plaque Psoriasis (3) Juvenile Psoriatic Arthritis (2) Psoriasis Vulgaris (2) Hidradenitis Suppurativa (2) Arthritis, Psoriatic (2) Psoriatic Arthritis (2) Non-radiographic Axial Spondyloarthritis (1) Autoimmunity, Inflammation (1) Polymyalgia Rheumatica (1)
antibody (9), small molecule (2), mixed (1), protein or peptide (1)
Celltrion (2) Novartis (1) Psoriasis Treatment Center of Central New Jersey (1) MoonLake Immunotherapeutics (1) Suzhou Suncadia Biopharmaceuticals (1) First Hospital of China Medical University (1) Biocad (1) UCB Biopharma SRL (1) Eli Lilly (1) Zura Bio (1) Sinocelltech (1) Taizhou Mabtech Pharmaceutical (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.